APRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aprea Therapeutics Inc (APRE) is not a strong buy at this time for a beginner investor with a long-term focus. The stock's technical indicators are bearish, financial performance is weak, and the recent financing dilution has negatively impacted the stock's outlook. While there are some positive catalysts, such as insider buying and promising clinical developments, the overall sentiment and performance do not align with a strong buy recommendation.
The technical indicators for APRE are bearish. The MACD is below zero and contracting negatively, RSI is neutral at 46.921, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 0.626 and resistance at 0.705.
Insider buying has increased by 147.37% in the last month.
The company raised $30 million in oversubscribed financing, extending its cash runway into early
Promising clinical developments, including partial response in Phase 1 trials for APR-1051.
Significant dilution from recent financing through pre-funded warrants and common share warrants.
Analysts have consistently lowered price targets, citing dilution concerns.
Weak trading trends with hedge funds remaining neutral and no significant trading activity.
The company's financial performance in Q4 2025 is weak. Revenue dropped by 98.38% YoY to 3337. Net income fell by 15.17% YoY to -2,455,630. EPS declined by 34.69% YoY to -0.32. Gross margin remained flat at 100%.
Analysts maintain a Buy or Outperform rating but have significantly lowered price targets due to dilution concerns. H.C. Wainwright reduced the price target from $4 to $1.20, and Wedbush reduced it from $11 to $7.
